Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
XORI Corporation is a venture capital organization that focuses on the incubation and funding of early-stage biotech companies. Established under the umbrella of Accelerator Life Science Partners, which was founded in 2003 in Seattle, WA, XORI Corporation plays a pivotal role in the life sciences sector. The organization is dedicated to creating and co-managing emerging biotech companies, providing essential business, scientific, and financial support to foster innovation.
As of now, XORI Corporation manages a fund size of $63 million, which is allocated to support startups primarily in North America. The firm has a capital-efficient model that emphasizes building companies from research intellectual property rather than merely investing in existing founders. This approach allows XORI to navigate the complexities of the biotech landscape effectively.
Notable milestones include the launch of XORI, a monoclonal antibody discovery platform that targets critical areas such as cancer therapy, immune disorders, and infectious diseases. The firm’s connection to top-tier research institutions, particularly the University of Washington, enhances its ability to identify and finance promising biotechnologies.
XORI Corporation's investment strategy is centered on early-stage biotechnology, particularly in the biotherapeutics and life sciences sectors. The firm primarily invests in seed and Series A stages, focusing on startups that are developing innovative solutions in critical areas such as cancer therapy, immune disorders, and infectious diseases. This targeted approach allows XORI to support companies that are at the forefront of medical advancements.
The organization seeks to partner with founders who demonstrate a strong commitment to their vision and possess the technical expertise necessary to drive their projects forward. XORI Corporation values capital-efficient business models and aims to provide comprehensive support that includes business development, scientific guidance, and financial resources. This holistic support structure is designed to accelerate the growth of its portfolio companies and enhance their chances of success in a competitive market.
XORI Corporation has been instrumental in the launch of its sole known portfolio company, XORI, which operates as a monoclonal antibody discovery platform. This platform focuses on developing therapies for cancer, immune disorders, and infectious diseases. The company has successfully navigated the early stages of funding and development, showcasing XORI Corporation's commitment to fostering innovative biotech solutions.
While additional portfolio companies have not been publicly disclosed, XORI Corporation's model emphasizes the creation of new ventures from research intellectual property. This approach allows the firm to maintain a dynamic portfolio that can adapt to emerging trends in the biotech sector.
Thong Q. Le - CEO. Thong has extensive experience in the biotech sector and has been instrumental in guiding XORI Corporation's strategic direction.
David McElligot - CSO. David brings a wealth of scientific expertise to the organization, focusing on the development of innovative biotherapeutics.
Lindsay Rain - CFO. Lindsay oversees the financial operations of XORI Corporation, ensuring effective management of the firm's capital resources.
David Schubert - COO. David is responsible for the operational aspects of the firm, facilitating the growth and development of portfolio companies.
XORI Corporation runs a program under its own name, focusing on the incubation and funding of early-stage biotech companies. This program is designed to provide startups with essential business, scientific, and financial support to foster innovation in the life sciences sector.
Eligibility for participation in the program typically includes having a strong research foundation and a clear business model aimed at addressing significant healthcare challenges. Interested founders should reach out to XORI Corporation for specific application details.
In 2015, XORI Corporation completed $62.8 million in funding across various biotech startups, signaling its active role in the investment landscape. This funding round was oversubscribed, indicating strong interest from investors in the biotech sector.
Recently, XORI Corporation has been involved in the launch of its portfolio company, XORI, which focuses on monoclonal antibody discovery. This initiative highlights the firm's commitment to supporting innovative solutions in healthcare.
What are XORI Corporation's investment criteria?
XORI Corporation primarily invests in early-stage biotech companies, focusing on seed and Series A rounds. The firm looks for startups that are developing innovative solutions in biotherapeutics and life sciences, particularly in areas such as cancer therapy and immune disorders.
How can founders pitch to XORI Corporation?
Founders interested in pitching to XORI Corporation should prepare a detailed presentation that outlines their business model, scientific approach, and market potential. A clear articulation of the problem being solved and the innovative aspects of the solution is crucial.
What makes XORI Corporation different from other investors?
XORI Corporation distinguishes itself through its capital-efficient model, which focuses on building companies from research intellectual property rather than simply investing in existing startups. This allows for a more hands-on approach in nurturing new ventures.
What is the geographic focus of XORI Corporation?
The firm primarily invests in North America, leveraging its connections to top research institutions and biotech hubs in the region.
What kind of support does XORI Corporation provide to its portfolio companies?
XORI Corporation offers comprehensive support that includes business development, scientific guidance, and financial resources. This support is designed to help startups navigate the complexities of the biotech landscape and accelerate their growth.
What is the fund size of XORI Corporation?
The current fund size of XORI Corporation is $63 million, which is allocated to support early-stage biotech companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.